Records containing: Nonalcoholic Steatohepatitis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-12-24An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)
-
CLINICAL_TRIALS study record update · 2024-12-19Contribution of De Novo Lipogenesis in Severity of Nonalcoholic Fatty Liver Disease
-
CLINICAL_TRIALS study record update · 2024-12-19Nutrient Overload, Insulin Resistance, and Hepatic Mitochondrial Dysfunction
-
CLINICAL_TRIALS study record update · 2024-12-04Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
-
CLINICAL_TRIALS study record update · 2024-11-25Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-10-24A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
-
CLINICAL_TRIALS study record update · 2024-10-09A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Doses of Kylo-0603 Capsules in Healthy Subjects
-
CLINICAL_TRIALS study record update · 2024-09-25A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, First-Time-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ecc0509 in Healthy Volunteers
-
CLINICAL_TRIALS study record update · 2024-09-19Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients with Clinical Evidence for NAFLD: Supporting the Disease Staging Into Fatty Liver Disease Versus NASH
-
CLINICAL_TRIALS study record update · 2024-05-24Aspirin in Adults With Nonalcoholic Fatty Liver Disease
-
CLINICAL_TRIALS study record update · 2024-05-17A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 3-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH)
-
CLINICAL_TRIALS study record update · 2024-04-29A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
-
CLINICAL_TRIALS study record update · 2024-03-29Efficacy and Safety of Dapagliflozin in Non-alcoholic Steatohepatitis: a Multicentre, Randomized, Placebo-controlled Trial
-
CLINICAL_TRIALS study record update · 2024-03-06Understanding the Metabolic Pathology of Pediatric Obesity and NAFLD
-
CLINICAL_TRIALS study record update · 2024-02-20Double-blind, Randomised, Placebo-controlled, Phase IIb Trial on the Efficacy and Safety of Norursodeoxycholic Acid Tablets in Patients With Non-alcoholic Steatohepatitis (NASH)
-
CLINICAL_TRIALS study record update · 2024-02-20Effect of 12-week Intermittent Calorie Restriction on Liver Fat Content in Comparison With Standard-of-care in Patients With Nonalcoholic Fatty Liver Disease: a Randomized Controlled Trial
-
CLINICAL_TRIALS study record update · 2024-01-24A Cluster Randomized Trial to Determine Diagnostic and Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)
-
CLINICAL_TRIALS study record update · 2023-11-15A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease
-
CLINICAL_TRIALS study record update · 2023-10-23A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
-
CLINICAL_TRIALS study record update · 2023-10-19Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods
-
CLINICAL_TRIALS study record update · 2023-08-09A Randomized, Open-label, Single Dose, Crossover Design Phase I Study to Evaluate Tolerability, Safety and Pharmacokinetics of HUYPS-1 in Healthy Volunteers
-
CLINICAL_TRIALS study record update · 2023-07-11Noninvasive Biomarkers of Metabolic Liver Disease 1.1
-
CLINICAL_TRIALS study record update · 2023-05-16Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Rosuvastatin Versus Coenzyme Q10 on Nonalcoholic Steatohepatitis
-
CLINICAL_TRIALS study record update · 2023-04-21Phase 2A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of CM-101 in Patients With Non-Alcoholic Steatohepatitis (NASH)
-
CLINICAL_TRIALS study record update · 2023-04-13A PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH)